BFM
MRSN

Boothbay Fund Management’s Mersana Therapeutics MRSN Stock Holding History

Boothbay Fund Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,622
Closed -$432K – 1860
2023
Q3 		$432K Buy
13,622
+13,221
+3,297% +$628K 0.01% 1098
2023
Q2 		$33K Buy
+401
New +$58.7K ﹤0.01% 1697
2021
Q4 		– Sell
-911
Closed -$215K – 2098
2021
Q3 		$215K Buy
911
+268
+42% +$78.3K 0.01% 1529
2021
Q2 		$218K Buy
+643
New +$243K 0.01% 1471
2021
Q1 		– Sell
-613
Closed -$297K – 1692
2020
Q4 		$408K Buy
+613
New +$341K 0.02% 830
2020
Q2 		– Sell
-484
Closed -$71K – 1059
2020
Q1 		$71K Buy
+484
New +$84.6K 0.01% 764

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's MRSN Position: Q4 2023 in Review

Boothbay Fund Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 13,622 shares — an estimated $432K sold.

Boothbay Fund Management first reported a position in MRSN in Q1 2020 and held it in 6 quarters. The position peaked at $432K in Q3 2023. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Boothbay Fund Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 13,622 Mersana Therapeutics shares in Q4 2023, an estimated $432K.
  • Boothbay Fund Management first reported a position in Mersana Therapeutics in Q1 2020 and held it in 6 quarters.
  • Boothbay Fund Management's Mersana Therapeutics position peaked at $432K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.